Avails Medical, a pioneer in automated, accelerated antibiotic susceptibility testing (AST) for septic patients announced today the participation of OMRON VENTURES Co., Ltd. in its current equity financing round.
| MENLO PARK, Calif., March 24, 2020 /PRNewswire/ -- Avails Medical, a pioneer in automated, accelerated antibiotic susceptibility testing (AST) for septic patients announced today the participation of OMRON VENTURES Co., Ltd. in its current equity financing round. The current investment round will allow Avails Medical to accelerate the development of its AST product pipeline, including the eQuant system, which was announced at ECCMID 2019. eQuant automates and closes the 24 hour workflow gap between rapid identification (ID) methods and legacy AST systems by providing a standardized inoculum (McFarland) directly from a positive blood culture in as fast as 1 hour. The McFarland standard is required in any conventional AST to ensure accurate results. “As a leader in automation and healthcare, we are excited to join Avails in the fight against antibiotic resistance. Their revolutionary approach will transform hospital lab workflow and bring it to the 21st century, allowing hospitals to turn their outdated system into rapid ones overnight”, said Tomoko Inoue, CEO of OMRON VENTURES. “OMRON’s mission to improve lives and contribute to a better society is aligned with Avails’ focus to fight the biggest global health threat – antibiotic resistance,” said Oren Knopfmacher, PhD, CEO and co-founder of Avails Medical. “This collaboration will allow Avails to learn from a true medical visionary and healthcare market leader, and together, collaboratively fight back against the rapid spread of antibiotic resistance’’. About Avails Medical About OMRON VENTURES SOURCE Avails Medical, Inc. |
View original content:
